Current status,opportunities,and challenges of CAR-NK cell therapy for solid tumors
10.3872/j.issn.1007-385x.2025.01.001
- VernacularTitle:CAR-NK细胞治疗实体瘤的现状、机遇与挑战
- Author:
Yanfang LIU
1
;
Xuetao CAO
1
Author Information
1. 海军军医大学 免疫与炎症全国重点实验室,上海 200433
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor(CAR);
CAR-NK cell;
tumor immunotherapy;
cell therapy;
solid tumor
- From:
Chinese Journal of Cancer Biotherapy
2025;32(1):1-8
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor natural killer(CAR-NK)cell therapy,as an emerging cellular immunotherapy strategy,has demonstrated a broader clinical application potential compared to CAR-T cell therapy due to its high safety profile and the unique advantages of'off-the-shelf'preparation.This article thoroughly discusses the antitumor mechanisms of CAR-NK cells,elucidating their targeted recognition mechanism,inherent cytotoxic activity,and the latest advancements in optimizing specific receptors to enhance their adaptability within the tumor microenvironment.Additionally,it provides an in-depth analysis of the advantages and challenges of various sources for CAR-NK cells,including peripheral blood,umbilical cord blood,induced pluripotent stem cells(iPSCs),and NK-92 cells,while summarizing their major challenges in the tumor immune microenvironment,such as insufficient persistence,immune suppression,and antigen heterogeneity.Finally,this article presents the therapeutic potential,limitations,and future perspectives of CAR-NK therapy in treating solid tumors,with a focus on its ongoing development and clinical translation.
